We are live on
!
Find out more
Aberdeen Group Portfolio holdings
AUM
$61.9B
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+5.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+93.17%
5 Year Est. Return
+119.65%
10 Year Est. Return
–
AUM
$64.6B
AUM Growth
+$1.37B
(+2.2%)
Cap. Flow
-$686M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
38.17%
Holding
995
New
43
Increased
362
Reduced
491
Closed
59
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nu Holdings
NU
|
+$36.3M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$36.1M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$35.6M |
| 4 |
Danaher
DHR
|
+$30.5M |
| 5 |
uniQure
QURE
|
+$28.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$93.5M |
| 2 |
Mercado Libre
MELI
|
+$86M |
| 3 |
Microsoft
MSFT
|
+$62.9M |
| 4 |
Apple
AAPL
|
+$55.6M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$48.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.59% |
| 2 | Healthcare | 13.39% |
| 3 | Consumer Discretionary | 11.41% |
| 4 | Communication Services | 11.25% |
| 5 | Financials | 10.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Waste Management
WM
$95B
| $125M | 0.19% |
567,539
+40,666
| +8% | +$8.67M |
|
102
Simon Property Group
SPG
$76.4B
| $124M | 0.19% |
669,834
-9,702
| -1% | -$1.76M |
|
103
Nike
NKE
$64.1B
| $122M | 0.19% |
1,914,243
+72,681
| +4% | +$4.74M |
|
104
Blackrock
BLK
$167B
| $122M | 0.19% |
113,621
-1,925
| -2% | -$2.1M |
|
105
AT&T
T
$164B
| $121M | 0.19% |
4,883,359
-54,349
| -1% | -$1.38M |
|
106
Chevron
CVX
$382B
| $120M | 0.19% |
790,382
-21,120
| -3% | -$3.22M |
|
107
Vertex Pharmaceuticals
VRTX
$123B
| $119M | 0.18% |
262,057
-52,832
| -17% | -$22.8M |
|
108
Johnson Controls International
JCI
$85.1B
| $118M | 0.18% |
982,563
-47,419
| -5% | -$5.44M |
|
109
Pinduoduo
PDD
$126B
| $115M | 0.18% |
1,013,878
-214,315
| -17% | -$26.6M |
|
110
RTX Corp
RTX
$290B
| $114M | 0.18% |
619,893
+4,549
| +0.7% | +$790K |
|
111
Realty Income
O
$61.1B
| $113M | 0.17% |
2,001,430
+56,476
| +3% | +$3.27M |
|
112
Capital One
COF
$128B
| $113M | 0.17% |
465,280
-8,526
| -2% | -$1.9M |
|
113
Philip Morris
PM
$309B
| $113M | 0.17% |
701,413
-89,923
| -11% | -$13.9M |
|
114
Blackstone
BX
$104B
| $112M | 0.17% |
724,986
+20,586
| +3% | +$3.13M |
|
115
Palo Alto Networks
PANW
$256B
| $111M | 0.17% |
601,775
+2,632
| +0.4% | +$531K |
|
116
Progressive
PGR
$128B
| $109M | 0.17% |
480,224
+2,227
| +0.5% | +$503K |
|
117
Williams Companies
WMB
$85.8B
| $106M | 0.16% |
1,763,084
+64,026
| +4% | +$3.87M |
|
118
Autodesk
ADSK
$51.8B
| $105M | 0.16% |
353,108
-875
| -0.2% | -$265K |
|
119
Stryker
SYK
$135B
| $104M | 0.16% |
295,845
-12,821
| -4% | -$4.67M |
|
120
Elevance Health
ELV
$81.5B
| $101M | 0.16% |
288,976
+16,540
| +6% | +$5.59M |
|
121
Becton Dickinson
BDX
$46.4B
| $99.3M | 0.15% |
511,452
-4,632
| -0.9% | -$881K |
|
122
Parker-Hannifin
PH
$120B
| $98.5M | 0.15% |
112,099
-1,102
| -1% | -$902K |
|
123
Cummins
CMI
$83.6B
| $97.9M | 0.15% |
191,721
-4,465
| -2% | -$2.09M |
|
124
Ecolab
ECL
$79.8B
| $96.6M | 0.15% |
367,850
+528
| +0.1% | +$141K |
|
125
Ford
F
$60.9B
| $96.1M | 0.15% |
7,323,552
-77,563
| -1% | -$1M |
|
Similar funds
Aberdeen Group's Q4 2025 Portfolio in Review
As of Q4 2025, Aberdeen Group held 995 positions worth $64.6B, up 2.2% from $63.2B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Aberdeen Group's Q4 2025 filing shows 43 new, 362 increased, 491 reduced and 59 closed positions. Its largest new stake was Praxis Precision Medicines: 134,992 shares worth $39.8M. The largest sale was Eli Lilly, an estimated $93.5M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Aberdeen Group's largest Q4 2025 buy was Praxis Precision Medicines: 134,992 shares worth $39.8M.
- Aberdeen Group added most to Nu Holdings in Q4 2025, an estimated $36.3M increase.
- Aberdeen Group's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $93.5M.
- Aberdeen Group fully exited BioMarin Pharmaceuticals in Q4 2025, selling an estimated $48.9M.
- Aberdeen Group's ten largest holdings make up 38% of its $64.6B portfolio in Q4 2025.
- Aberdeen Group opened 43 new positions and closed 59 in Q4 2025.
- Aberdeen Group's portfolio value rose 2.2% quarter-over-quarter to $64.6B.
Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.